
Download the app to access in-depth Shariah compliance reports for over 60,000 global stocks.
Get the App
IN8bio is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for cancer treatment. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product in Phase I clinical trial for glioblastoma and solid tumors, and INB-100, an allogeneic product in Phase I clinical trial for acute leukemia. The company is also developing INB-400 and INB-300 in preclinical phase for various solid tumor cancers.